Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vishal Gupta

Gastroenterology Orange City, FL Medical Doctor

NPI 1255449179 CMS profile 11387

2884 Wellness Ave Ste 100, Suite 100, Orange City, FL 32763

Open in the dashboard

General payments

$24,697

392 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$871,608 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Vishal Gupta of Orange City, FL is reported in the CMS Open Payments database as having received $24,697 across 392 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $871,608 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,495 71
2024 General $4,151 85
2023 General $5,944 51
2022 General $763 46
2021 General $916 56
2020 General $570 34
2019 General $857 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vishal Gupta
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Vishal Gupta were reported at $11,495. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Vishal Gupta Gastroenterology median Middle half National median
2019 $857 $417 $126–$1,100 $163
2020 $570 $224 $74–$624 $114
2021 $916 $352 $106–$1,054 $132
2022 $763 $448 $129–$1,270 $149
2023 $5,944 $533 $150–$1,390 $160
2024 $4,151 $605 $160–$1,606 $164
2025 $11,495 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $17,656 37 payments
  2. AbbVie, Inc. $2,076 136 payments
  3. Phathom Pharmaceuticals, Inc. $658 7 payments
  4. Janssen Biotech, Inc. $515 24 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $407 25 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $280 16 payments
  7. Pfizer Inc. $266 16 payments
  8. UCB, Inc. $229 13 payments
  9. Gilead Sciences, Inc. $218 11 payments
  10. Lilly USA, LLC $191 4 payments
  11. Other $2,200 103 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16,800 9 payments
  2. Food and Beverage $7,783 379 payments
  3. Education $95 3 payments
  4. Consulting Fee $18 1 payment
Products named General payments · program years 2019–2025
  1. INTERSTIM $17,626 35 payments
  2. VOQUEZNA $658 7 payments
  3. RINVOQ $531 24 payments
  4. HUMIRA $460 31 payments
  5. SKYRIZI Immunology $452 42 payments
  6. MAVYRET $371 19 payments
  7. STELARA $371 15 payments
  8. LINZESS $317 23 payments
  9. TREMFYA $285 15 payments
  10. SKYRIZI Immunology $263 15 payments
  11. Other $4,413 224 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

834

Median for Gastroenterology: 569

Drug cost

$56,078

Median for Gastroenterology: $104,976

Branded share of claims

30.8%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 18 $22,678
Movantik Naloxegol Oxalate Brand 20 $9,936
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 97 $5,721
Omeprazole Generic 230 $3,533
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 19 $3,202
Pantoprazole Sodium Generic 178 $2,292
Colestipol Hcl Generic 21 $1,421
Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 11 $1,375
Sucralfate Generic 22 $1,128
Famotidine Generic 50 $795

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$416,216

Of which drugs: $71,455

Medicare patients

687

Average age 75

Services billed

9,798

405 women, 282 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 43%
Ischemic heart disease 43%
Chronic kidney disease 41%
COPD 34%
Depression 30%
Heart failure 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
$658 — —
RINVOQ
$123 — —
SKYRIZI
$115 — —
STELARA
$94 — —
TREMFYA
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

392 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record